Published in J Psychopharmacol on June 19, 2013
Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation. Pharmacoepidemiol Drug Saf (2014) 0.92
Risk based in vitro performance assessment of extended release abuse deterrent formulations. Int J Pharm (2016) 0.75
In response to Gudin et al - Comparing the effect of tampering on the oral pharmacokinetic profiles of two extended-release oxycodone formulations with abuse-deterrent properties. Pain Med (2016) 0.75
Intranasal Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users. Pain Med (2015) 0.75
How Resistant to Tampering are Codeine Containing Analgesics on the Market? Assessing the Potential for Opioid Extraction. Pain Ther (2016) 0.75
The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol (2006) 30.90
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Rat toxicogenomic study reveals analytical consistency across microarray platforms. Nat Biotechnol (2006) 5.14
Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA (2006) 3.49
The balance of reproducibility, sensitivity, and specificity of lists of differentially expressed genes in microarray studies. BMC Bioinformatics (2008) 2.54
Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study. Clin J Pain (2007) 2.07
Microarray scanner calibration curves: characteristics and implications. BMC Bioinformatics (2005) 2.02
ArrayTrack: an FDA and public genomic tool. Methods Mol Biol (2009) 1.71
Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans. Genome Res (2009) 1.60
Gender differences in pharmacokinetics and pharmacodynamics of zolpidem following sublingual administration. J Clin Pharmacol (2013) 1.16
Pharmacokinetics, tolerability, and safety of intranasal administration of reformulated OxyContin(®) tablets compared with original OxyContin (®) tablets in healthy adults. Clin Drug Investig (2013) 1.10
Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users. J Clin Pharmacol (2013) 0.93
atBioNet--an integrated network analysis tool for genomics and biomarker discovery. BMC Genomics (2012) 0.85
Effect of ketoconazole on the pharmacokinetic profile of buprenorphine following administration of a once-weekly buprenorphine transdermal system. Clin Drug Investig (2012) 0.84
Influence of food on pharmacokinetics of zolpidem from fast dissolving sublingual zolpidem tartrate tablets. J Clin Pharmacol (2013) 0.79
Once-weekly transdermal buprenorphine application results in sustained and consistent steady-state plasma levels. J Pain Symptom Manage (2012) 0.78
Pharmacokinetics of zolpidem from sublingual zolpidem tartrate tablets in healthy elderly versus non-elderly subjects. Drugs Aging (2014) 0.77
The pharmacokinetics and safety of single escalating oral doses of eletriptan. J Clin Pharmacol (2002) 0.76
SNPTrack™ : an integrated bioinformatics system for genetic association studies. Hum Genomics (2012) 0.75
Abuse potential of intravenous oxycodone/naloxone solution in nondependent recreational drug users. Clin Drug Investig (2014) 0.75